Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral ComplicationsInvivoscribe Marketing2021-02-11T21:56:18-08:00March 1st, 2020|Read more
Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patientsInvivoscribe Marketing2021-02-11T21:58:45-08:00February 6th, 2020|Read more
Monitoring minimal residual disease in the bone marrow using next generation sequencingInvivoscribe Marketing2021-02-11T22:00:56-08:00January 17th, 2020|Read more
Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal SequenceInvivoscribe Marketing2021-02-11T23:36:10-08:00November 13th, 2019|Read more
Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implicationsInvivoscribe Marketing2021-02-11T23:40:44-08:00October 15th, 2019|Read more
Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kitswmm2021-02-26T19:14:11-08:00January 31st, 2017|Read more
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosiswmm2021-02-26T19:14:23-08:00November 14th, 2016|Read more
Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Developmentwmm2021-02-26T19:14:30-08:00May 31st, 2016|Read more
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Positionwmm2021-02-26T19:14:37-08:00March 28th, 2016|Read more
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)wmm2021-02-26T19:14:49-08:00February 18th, 2016|Read more